MedTrace Logo

Irinotecan and Temozolomide for Ewing Sarcoma

NCT03359005 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-11-01

No results posted yet for this study

Summary

The investigators explored the activity of vincristine and irinotecan combined with temozolomide (VIT) in patients with relapsed and metastatic Ewing Sarcoma.

Conditions

  • Ewing Sarcoma

Interventions

DRUG

Vincristine

vincristine 1.5mg/m2 iv D1,D8

DRUG

Temozolomide

Temozolomide 100mg/m2/d iv on days 1-5.

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Wei Guo, Ph.D, M.D. · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2022-11-28
Completion
2025-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03359005 on ClinicalTrials.gov